Clinical Trials Logo
  1. Home
  2. Metastases, Neoplasm
  3. NCT05419518

Palliative Dose Escalated Radiation for Painful Non-Spine Bone Metastases and Painful Non-Bone Metas

Metastases, Neoplasm Clinical Trial

Official title:
Palliative Dose Escalated Radiation for Painful Non-Spine Bone Metastases and Painful Non-Bone Metastases

Clinical Trial Summary

The investigators hypothesize that with dose escalation to 40-50 Gy in ten fractions, the complete pain response rate at one month can be increased to 40-50% in painful non-spinal bone metastases. Additionally, the investigators hypothesize that utilizing a fractionation scheme with an escalated biologically equivalent dose (BED) will result in a higher proportion of participants responding to treatment, and will also lead to more durable responses. Furthermore, the investigators hypothesize that with dose escalation to 40-50 Gy in ten fractions, the complete pain response rate at one month can be increased to 35-45% in painful non-bone metastases

Clinical Trial Description

The purpose of this study is to prospectively evaluate dose escalation and pain response in patients with painful non-spinal bone metastases and painful non-bone metastases treated with radiation therapy. Primary Objective: To evaluate improvement of complete pain response rate in painful non-spine bone metastases and painful non-bone metastases with dose escalated radiation using a ten fraction radiation regimen Secondary Objectives: To evaluate best pain response To evaluate mean pain scores To evaluate the duration of pain response To evaluate the changes in quality-of-life following radiation To evaluate the rates of retreatment with radiation secondary to disease or symptom progression To evaluate treatment related toxicity ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05419518
Study type Interventional
Source Rutgers, The State University of New Jersey
Contact Matthew P Deek, MD
Phone 732-253-3941
Email Deekmp@cinj.Rutgers.edu
Status Recruiting
Phase Phase 2
Start date March 16, 2023
Completion date April 1, 2024
View Details
See also
  Status Clinical Trial Phase
Terminated NCT00065117 - Safety, Tolerability and Efficacy of ZD6126 in Combination With Oxaliplatin, 5-Fluorouracil and Leucovorin in Subjects With Metastatic Colorectal Cancer. Phase 2
Completed NCT00039780 - Evaluation of BNP7787 for the Prevention of Neurotoxicity in Metastatic Breast Cancer Patients Receiving Weekly Paclitaxel Phase 3
Terminated NCT00048893 - Vaccine and Chemotherapy for Previously Untreated Metastatic Breast Cancer Phase 1/Phase 2
Completed NCT00037869 - High Dose I-131 Metaiodobenzylguanidine(MIBG) for Metastatic Neuroendocrine Tumors Phase 3
Completed NCT02265549 - Radiomics for Prediction of Long Term Survival and Local Failure After Stereotactic Radiotherapy for Brain Metastases N/A
Completed NCT00034918 - This Study is to Assess the Efficacy and Safety of ZD6474 in Subjects With Metastatic Breast Cancer Phase 2
Completed NCT01115751 - A Study in Patients With Advanced or Metastatic Cancer Phase 1
Terminated NCT01115803 - A Study of LY2584702 With Erlotinib or Everolimus in Participants With Solid Tumors Phase 1
Completed NCT00056173 - Combination of Capecitabine and GTI-2040 in the Treatment of Renal Cell Carcinoma Phase 1/Phase 2
Terminated NCT00034697 - Study of Temozolomide in the Treatment of Brain Metastasis From Non-small-cell Lung Cancer (Study P02143) Phase 2
Completed NCT00055471 - A Phase IIa. Open-label, Multicenter, Dose-escalation Study to Assess the Tolerability and Pharmacokinetics of ZD4054 (Zibotentan) Given Orally Once Daily in Subjects With Metastatic Prostate Cancer Phase 2
Completed NCT00046514 - ABI-007 in Taxol Resistant Patients With Metastatic Breast Cancer Phase 2
Completed NCT00046527 - Study of ABI-007 and Taxol in Patients With Metastatic Breast Cancer Phase 3
Completed NCT00041808 - Magnetic-Targeted Doxorubicin in Treating Patients With Cancer Metastatic to the Liver Phase 1/Phase 2
Completed NCT00037609 - Safety, Efficacy and Pharmacokinetic Between Capecitabine and Exisulind in Metastatic Breast Cancer Patients Phase 1/Phase 2
Withdrawn NCT00038038 - Assessment of Head and Neck Tumor Hypoxia Using 18F-Fluoromisonidazole N/A
Completed NCT03670992 - Surgical Treatment of Pancreatic RCC Metastases
Terminated NCT00050336 - Study of Lonafarnib in Combination With Paclitaxel and Carboplatin in Patients With Non-Small Cell Lung Cancer (Study P01901)(TERMINATED) Phase 3
Recruiting NCT03563326 - Intraperitoneal Infusion of EpCAM CAR-T Cell in Advanced Gastric Cancer With Peritoneal Metastasis (WCH-GC-CART) Phase 1
Completed NCT00044863 - Study of Erbitux (Cetuximab) in Patients With Metastatic Colorectal Carcinoma Phase 2